Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
about
Therapeutic Approach to Adult Fibrotic Lung DiseasesRole of Receptor Tyrosine Kinase Signaling in Renal FibrosisCell-Based Therapy for SilicosisThe IL-1 cytokine family and its role in inflammation and fibrosis in the lungIdiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanibPharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteineNintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosisIs there still hope for single therapies: how do we set up experimental systems to efficiently test combination therapies?Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosisA high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptorRisk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis.Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments.The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processesProtective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice.New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.Nintedanib in the treatment of idiopathic pulmonary fibrosis.Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosisAttenuating endogenous Fgfr2b ligands during bleomycin-induced lung fibrosis does not compromise murine lung repairThe future of the development of medicines in idiopathic pulmonary fibrosis.Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction ModelIncreased FGF1-FGFRc expression in idiopathic pulmonary fibrosis.Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.Quantification of Pulmonary Fibrosis in a Bleomycin Mouse Model Using Automated Histological Image AnalysisDasatinib inhibits TGFβ-induced myofibroblast differentiation through Src-SRF Pathway.Novel Mechanisms for the Antifibrotic Action of Nintedanib.Keloids: Animal models and pathologic equivalents to study tissue fibrosis.Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease.Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma.New renal drug development to face chronic renal disease.Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies.Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.The potential role of IL-33/ST2 signaling in fibrotic diseases.Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapiesNintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.The myofibroblast, a key cell in normal and pathological tissue repair.Nintedanib reduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway.Radiation induced pulmonary fibrosis as a model of progressive fibrosis: Contributions of DNA damage, inflammatory response and cellular senescence genes.
P2860
Q26741569-AF9E0F10-5251-4ABA-B52C-52E3468228D4Q26743407-52555251-8D62-49E3-A791-0EFBEE07B1C8Q26749489-0744CAA8-0E63-4CA3-83FB-B670AE4B412CQ26752849-E8DF6B15-0D81-435A-8CAB-51388301D844Q26771647-1ECD0A80-0180-494B-B5A4-A06338E6011EQ26777928-12A93CB2-ACAA-439B-82CD-678AD83D28E9Q26783169-2F0D0C4C-D52B-44BA-9703-59B03F3D02AEQ26998459-EDE4E1DE-DA86-4523-8980-169F27E80B7DQ27333960-33A8FBF5-610A-4B75-B63E-293D93F6ED50Q28828478-A3139C44-8849-42BE-84A0-80C6ACCD0FD2Q30249619-2BCF0C09-C10A-4793-B584-7E61EEAFB9F7Q30398970-69B85301-0989-4BBD-8DB3-DA79C8D9CE3FQ33601748-EF886C82-CA0A-4BB0-BD47-2AC1C536BD07Q33794090-E060A715-589A-4AEA-894D-CAAF9FAA1E2BQ34432217-B9C3D085-AB52-433E-8923-1476762A68CDQ34471193-65BCF0E7-0814-4E99-9ECE-511D1950BA41Q35558781-A4419950-D262-42E2-A179-4E336D73274AQ35622495-CCBE42B8-3BAF-4954-B62C-0D1EC65DDC43Q35785682-22D6E35D-6CFB-4D45-9E2E-646C09AC41E1Q35803480-3FE7E21D-3263-4BBD-AC33-37E99F959D19Q35830712-DA24F2CA-524F-41F5-8560-173F7ACF478CQ36089113-4D15C41E-52D0-41E5-B32F-8C015093BB06Q36256033-D690D746-EED7-40FA-8D29-3C67D91B6A12Q36373463-662E5F97-6C60-45D4-B77D-95D69C33BB6CQ36549047-0B2A9BDF-EF9A-434D-A22A-5461F20030CFQ36828407-51BD379A-4A95-496E-9483-DD57AB195E66Q36847599-550E0722-7C9D-41B6-9AF4-8FCC06EAD440Q37080510-05267CC4-C505-4124-8220-BCA54A430920Q37686313-48B051DD-BCD5-4355-B219-9888B95A104BQ38246640-4D450BE4-FEC8-4AAA-BF41-69BC7D058CBCQ38258904-9C22E71F-D9DD-47EC-A993-ADEE33AA23BCQ38268556-A623D34A-2D89-4F0A-97B4-69631897A269Q38366438-EDB4BCAE-5FD8-4BA8-9270-8BBAEAD3BC5CQ38424483-3BE1853E-21F5-4548-AFB3-DE52225C24DEQ38448525-B168A97A-51A9-4BAA-A95E-FC05D18F3046Q38524352-0DE1A5D5-3071-4761-9F96-E0CB33C1DC86Q38580461-86FEED16-CB03-4291-B15B-4BB2E43A1FB6Q38673061-025CD579-7E11-417E-B441-418FD3964421Q38734546-3CD4DFE8-7969-482D-8171-04A6518BDA4BQ38769339-8D4D89B7-89D4-4702-B56A-B802757B109B
P2860
Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@ast
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@en
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@nl
type
label
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@ast
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@en
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@nl
prefLabel
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@ast
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@en
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@nl
P2093
P356
P1476
Antifibrotic and anti-inflamma ...... ental models of lung fibrosis.
@en
P2093
Alexander Holweg
Isabelle Maillet
Lutz Wollin
P304
P356
10.1124/JPET.113.208223
P407
P577
2014-02-20T00:00:00Z